Bone Biologics Corp (BBLG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bone Biologics Corporation on June 8, 2022, reporting events occurring on that date. The Company, incorporated in Delaware, is engaged in the development of licensed products and trades on The Nasdaq Stock Market LLC under the symbols BBLG (Common Stock) and BBLGW (Warrants).
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on a material definitive agreement regarding future contingent payments.
Material Changes and Agreements
On June 8, 2022, the Company entered into a Third Amendment to an Amended License Agreement with UCLA Technology Development Group (UCLA TDG), effective May 9, 2022. Key terms include:
- Diligence Fee Obligation: The Company agreed to pay a total of $8,000,000 to UCLA TDG in partial consideration for lost patent lifetime.
- Payment Deferral: To preserve capital for product development, payment is deferred until a "Triggering Sale Date" (the first sale of any Licensed Product).
- Payment Schedule:
- $2,000,000 due upon cumulative Net Sales of $50,000,000.
- $2,000,000 due upon cumulative Net Sales of $100,000,000.
- $4,000,000 due upon cumulative Net Sales of $200,000,000.
- Survival and Transfer: The obligation survives termination of the agreement. The Company cannot transfer assets related to Licensed Products without either transferring this fee obligation or paying the full fee within 10 days of the transfer.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance or management commentary regarding future performance. The primary risk disclosed is the contingent liability of up to $8,000,000, which will impact future cash flows upon the commercialization of Licensed Products. The agreement restricts the Company's ability to sell or assign assets related to the Licensed Products without satisfying the fee obligation.
Investor Verification Checklist
- Verify the current status of the Company's Licensed Products and proximity to a "Triggering Sale Date."
- Review the full text of the Third Amendment (Exhibit 10.1) for additional covenants or definitions of "Net Sales."
- Assess the Company's current cash position to determine if it can sustain operations without immediate revenue to fund the development milestones.
- Monitor future filings for any sales of Licensed Products that would activate the payment schedule.